Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.41 |
| ▸ | GABRP | O00591 | 2/20 | 0.41 |
| ▸ | GABRD | O14764 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.41 |
| ▸ | GABRE | P78334 | 2/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.41 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.41 |
| ▸ | RRM1 | P23921 | 1/20 | 0.40 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21122518 | 1.00 | GABRR1 (0.46) | GABRR1DPP7GABRPGABRDGABRA1 | |
| SCHEMBL12278736 | 1.00 | GABRR1 (0.46) | GABRR1DPP7GABRPGABRDGABRA1 | |
| SCHEMBL12280588 | 0.86 | GSR (0.50) | GABRR1DPP7GABRPGABRDGABRA1 | |
| SCHEMBL17173859 | 0.86 | GSR (0.50) | GABRR1DPP7GABRPGABRDGABRA1 | |
| SCHEMBL12278737 | 0.86 | GSR (0.50) | GABRR1DPP7GABRPGABRDGABRA1 | |
| SCHEMBL13337173 | 0.84 | GSR (0.59) | DPP7GSRDPP8DPP9 | |
| SCHEMBL10046226 | 0.84 | GSR (0.59) | DPP7GSRDPP8DPP9 | |
| SCHEMBL10046228 | 0.84 | GSR (0.59) | DPP7GSRDPP8DPP9 | |
| SCHEMBL23762407 | 0.82 | GSR (0.57) | DPP7GSRDPP8DPP9 | |
| SCHEMBL13429506 | 0.82 | GSR (0.57) | DPP7GSRDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786547-B2 | Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds | SYNEDGEN, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11786547-B2 | Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds | SYNEDGEN, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11717532-B2 | Methods and compositions for treating wounds utilizing chitosan compounds | SYNEDGEN, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11717532-B2 | Methods and compositions for treating wounds utilizing chitosan compounds | SYNEDGEN, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230201248-A1 | COMPOSITIONS AND METHODS OF USE THEREOF | SYNEDGEN, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230201248-A1 | COMPOSITIONS AND METHODS OF USE THEREOF | SYNEDGEN, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20210386774-A1 | METHODS FOR TREATMENT OR PREVENTION OF DAMAGE RESULTING FROM RADIATION, TRAUMA OR SHOCK | SYNEDGEN, INC. | 2021-12-16 | — | — | US | disclosed |
| EP-2897622-B1 | METHODS FOR TREATMENT OR PREVENTION OF DAMAGE RESULTING FROM RADIATION | SYNEDGEN INC (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3311823-B1 | METHODS AND COMPOSITIONS FOR DISRUPTING BIOFILM UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS | SYNEDGEN INC (US) | 2020-11-25 | — | — | EP | disclosed |
| US-10765616-B2 | Oral formulation of polyglucosamine derivatives in combination with a non-fermentable sugar | SYNEDGEN, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20120301408-A1 | ORAL CARE METHODS AND COMPOSITIONS UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS | UNITED STATES GOVERNMENT | 2012-11-29 | — | — | US | disclosed |
| US-20120295355-A1 | NUCLEIC ACID DELIVERY USING MODIFIED CHITOSANS | BAKER SHENDA (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120122943-A1 | Melampomagnolide B Derivatives as Antileukemic and Cytotoxic Agents | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2011028968-A1 | ORAL CARE METHODS AND COMPOSITIONS UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS | SYNEDGEN, INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2010088565-A1 | NUCLEIC ACID DELIVERY USING MODIFIED CHITOSANS | SYNEDGEN, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| US-20100137193-A1 | CHITOSAN DERIVATIVES TO TREAT ANIMALS OR OPTIMIZE ANIMAL HEALTH | SYNEDGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100130443-A1 | CHITOSAN DERIVATIVES, COMPOSITIONS AND RELATED METHODS OF USE | SYNEDGEN INC. (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2010056927-A1 | CHITOSAN DERIVATIVES ALONE OR IN COMBINATION FOR THE TREATMENT OF MDR MICROBIAL INFECTIONS | SYNEDGEN, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100056474-A1 | Methods and Compositions for the Prevention of and Treatment of Infections Utilizing Chitosan-Derivative Compounds | UNITED STATES GOVERNMENT | 2010-03-04 | — | — | US | disclosed |
| WO-2010021930-A1 | PREVENTION AND TREATMENT OF MRSA INFECTIONS WITH CHITOSAN-DERIVATIVES | SYNEDGEN, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210386774-A1 | METHODS FOR TREATMENT OR PREVENTION OF DAMAGE RESULTING FROM RADIATION, TRAUMA OR SHOCK | HMGB1, ELANE, SERPINB1 | GABRR1 2456/4885DPP7 2861/4885GABRP 3740/4885 |
| US-20100137193-A1 | CHITOSAN DERIVATIVES TO TREAT ANIMALS OR OPTIMIZE ANIMAL HEALTH | CHIT1, CHIA, ALG1 | GABRR1 3887/4885DPP7 461/4885GABRP 4337/4885 |
| US-20100056474-A1 | Methods and Compositions for the Prevention of and Treatment of Infections Utilizing Chitosan-Derivative Compounds | NRDC, ARG1, CHIA | GABRR1 2173/4885DPP7 864/4885GABRP 3376/4885 |
| US-20120301408-A1 | ORAL CARE METHODS AND COMPOSITIONS UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS | CHIT1, ALG1, SI | GABRR1 3308/4885DPP7 789/4885GABRP 3381/4885 |
| US-11717532-B2 | Methods and compositions for treating wounds utilizing chitosan compounds | CHIA, MMP8, CHIT1 | GABRR1 3639/4885DPP7 550/4885GABRP 4090/4885 |
| US-20230201248-A1 | COMPOSITIONS AND METHODS OF USE THEREOF | ENGASE, FUT5, ALG1 | GABRR1 3160/4885DPP7 595/4885GABRP 3596/4885 |
| US-11786547-B2 | Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds | CHIT1, ALG1, CSGALNACT1 | GABRR1 1985/4885DPP7 1094/4885GABRP 3252/4885 |
| US-10765616-B2 | Oral formulation of polyglucosamine derivatives in combination with a non-fermentable sugar | FUT6, FUT5, PGLS | GABRR1 3581/4885DPP7 754/4885GABRP 3524/4885 |
| US-20100130443-A1 | CHITOSAN DERIVATIVES, COMPOSITIONS AND RELATED METHODS OF USE | CHIT1, CHIA, ALG1 | GABRR1 2602/4885DPP7 550/4885GABRP 2355/4885 |
| US-20120122943-A1 | Melampomagnolide B Derivatives as Antileukemic and Cytotoxic Agents | MCL1, MYADM, BPGM | GABRR1 2947/4885DPP7 3827/4885GABRP 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.